Boston Scientific (BSX)
(Delayed Data from NYSE)
$68.62 USD
+0.68 (1.00%)
Updated Mar 27, 2024 04:00 PM ET
After-Market: $68.65 +0.03 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
Price, Consensus and EPS Surprise
BSX 68.62 +0.68(1.00%)
Will BSX be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for BSX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BSX
Abbott (ABT) Expands in Canada With First Eterna SCS Use
AHCO vs. BSX: Which Stock Is the Better Value Option?
BSX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Boston Scientific (BSX) Global Growth Robust, Macro Issues Ail
Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Other News for BSX
Piper says competitive process could materialize for ShockWave
Boston Scientific Corp. stock underperforms Wednesday when compared to competitors despite daily gains
Johnson & Johnson Strong Strategic Fit For Shockwave Medical, But Medtronic, Boston Scientific Could Be Other Bidder, Says Analyst
J&J-Shockwave deal makes strategic sense: analysts
Boston Scientific, Scivita Medical expand strategic cooperation arrangement